Oncology Xagena
Poly(ADP-ribose) polymerase ( PARP ) is implicated in DNA repair and transcription regulation. Niraparib is an oral potent, selective PARP-1 and PARP-2 inhibitor that induces synthetic lethality in pr ...
The PARP inhibitor, Olaparib ( Lynparza ) has shown clinical activity in subsets of recurrent ovarian cancer patients. Researchers have hypothesized increased DNA damage by Olaparib may complement a ...
Positive results from the phase 3 PAOLA-1 trial in women with advanced ovarian cancer. were announced. The trial, in the first-line maintenance setting, compared Olaparib ( Lynparza ) added to stand ...
The FDA ( U.S. Food and Drug Administration ) has approved Rubraca ( Rucaparib ) tablets for the treatment of adult patients with a deleterious BRCA mutation ( germline and/or somatic )-associated me ...
